Keerthana Sekar

Senior Research Associate at IGM Biosciences, Inc. - Mountain View, California, US

Keerthana Sekar's Colleagues at IGM Biosciences, Inc.
Avneesh Saini

Sr. Scientist (Downstream Process Development)

Contact Avneesh Saini

Anthony Nguyen

Sr Manufacturing Associate

Contact Anthony Nguyen

Kristina Khuu

Senior Manufacturing Associate

Contact Kristina Khuu

Genee Skulich

Senior Research Associate Upstream Process Sciences

Contact Genee Skulich

Greg DeLassus

Senior Patent Attorney

Contact Greg DeLassus

IGM Biosciences

Human Resources Coordinator

Contact IGM Biosciences

Bella N.

Lab Coordinator - Research & Development

Contact Bella N.

View All Keerthana Sekar's Colleagues
Keerthana Sekar's Contact Details
HQ
(650) 965-7873
Location
Company
IGM Biosciences, Inc.
Keerthana Sekar's Company Details
IGM Biosciences, Inc. logo, IGM Biosciences, Inc. contact details

IGM Biosciences, Inc.

Mountain View, California, US • 258 Employees
BioTech/Drugs

About IGM Biosciences, Inc. IGM Biosciences (Nasdaq: IGMS) is a clinical-stage biotechnology company committed to developing and delivering a new class of medicines to treat patients with autoimmune and inflammatory diseases. The Company’s pipeline of clinical and preclinical assets is based on the IgM antibody, which has 10 binding sites, compared to conventional IgG antibodies with only 2 binding sites. We have created unique IgM antibodies with high selectivity, affinity, and avidity that may redefine what is possible for therapeutic antibody medicines. We are committed to exploring how the unique structure and binding properties of the IGM antibody can improve outcomes for patients with these serious conditions. The Company also has an exclusive worldwide collaboration agreement with Sanofi to create, develop, manufacture, and commercialize IgM antibody agonists against oncology, immunology, and inflammation targets. For more information, please visit www.igmbio.com. Imvotamab in Autoimmune and Inflammatory Diseases Imvotamab is a bispecific T cell engaging IgM antibody targeting CD20 and CD3 proteins. We believe that Imvotamab, with its 10 binding units for CD20, may successfully bind to CD20 expressing B cells with more power (avidity) compared to an IgG bispecific antibody with only one or two binding units for CD20. Our preclinical studies suggest that Imvotamab may offer the potential for deeper depletion of B cells, including those in low CD20 expressing cells, than currently approved antibody therapies. We are evaluating Imvotamab in Phase 1b clinical trials of Imvotamab in severe systemic lupus erythematosus (SLE), rheumatoid arthritis (RA), and idiopathic inflammatory myopathies (myositis).

Lymphoma Treatment Hematologic Malignancies Autoimmune Disease
Details about IGM Biosciences, Inc.
Frequently Asked Questions about Keerthana Sekar
Keerthana Sekar currently works for IGM Biosciences, Inc..
Keerthana Sekar's role at IGM Biosciences, Inc. is Senior Research Associate.
Keerthana Sekar's email address is ***@igmbio.com. To view Keerthana Sekar's full email address, please signup to ConnectPlex.
Keerthana Sekar works in the BioTech/Drugs industry.
Keerthana Sekar's colleagues at IGM Biosciences, Inc. are Avneesh Saini, Anthony Nguyen, Kristina Khuu, Genee Skulich, Greg DeLassus, IGM Biosciences, Bella N. and others.
Keerthana Sekar's phone number is null
See more information about Keerthana Sekar